Identification of key pathways and genes in lung carcinogenesis

The present study aimed to identify key pathways and genes in the pathogenesis of lung cancer. The GSE10072 dataset was downloaded from the Gene Expression Omnibus database. Protein-protein interaction data were collected from Human Protein Reference Database, and 201 pathways were downloaded from the Kyoto Encyclopedia of Genes and Genomes database. Signaling network impact analysis was performed to identify enriched pathways, followed by the construction of a pathway-pathway crosstalk network. Benzopyrene was used to treat normal human lung cells at concentrations of 0.01, 0.1, 1 and 10 µM, and cell viability was measured. Furthermore, growth arrest and DNA damage inducible β (GADD45B), p53, cyclin B, Akt and nuclear factor (NF)-κB protein levels were also measured via western blotting. Impact analysis identified 11 enriched lung cancer-associated KEGG pathways, including ‘complement and coagulation cascades’, ‘ECM-receptor interaction’, ‘P53 signaling pathway’, ‘cell adhesion molecules’ and ‘focal adhesion’. In addition, cell cycle, ‘drug metabolism-cytochrome P450’, ‘metabolic pathways’, ‘pathways in cancer’, ‘focal adhesion’ and ‘antigen processing and presentation’ were central in the pathway-pathway cross-talk network. Furthermore, the upregulated gene GADD45B was associated with three of the pathways, including an activated pathway (‘MAPK signaling pathway’) and two repressed pathways (‘cell cycle’ and ‘P53 pathway’). Western blotting demonstrated that the expression of NF-κB, Akt and GADD45B increased over time in lung cells treated with benzopyrene, whereas the expression levels of cyclin B and P53 decreased. In conclusion, GADD45B may contribute to lung carcinogenesis via affecting the MAPK, P53 signaling and cell cycle pathways.

[1]  S. McGuire World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. , 2016, Advances in nutrition.

[2]  Tomasz Górecki,et al.  A comparison of tests for the one-way ANOVA problem for functional data , 2015, Comput. Stat..

[3]  J. Massagué,et al.  Structural determinants of Smad function in TGF-β signaling. , 2015, Trends in biochemical sciences.

[4]  G. Hussey,et al.  Translational regulation of Inhibin βA by TGFβ via the RNA-binding protein hnRNP E1 enhances the invasiveness of epithelial-to-mesenchymal transitioned cells , 2015, Oncogene.

[5]  L. Havel,et al.  Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity , 2014, Oncogene.

[6]  John D Lambris,et al.  Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression , 2012, The Journal of Immunology.

[7]  Xiao-guang Liu,et al.  High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer , 2012, Medical Oncology.

[8]  T. Libermann,et al.  GADD45 proteins: central players in tumorigenesis. , 2012, Current molecular medicine.

[9]  A. Zhavoronkov,et al.  Gadd45 proteins: Relevance to aging, longevity and age-related pathologies , 2012, Ageing Research Reviews.

[10]  M. Peppelenbosch,et al.  Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation. , 2010, Thrombosis research.

[11]  Adam M. Gustafson,et al.  Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development , 2010, Science Translational Medicine.

[12]  I. Kim,et al.  PTEN/pAkt/p53 signaling pathway correlates with the radioresponse of non-small cell lung cancer. , 2010, International journal of molecular medicine.

[13]  P. Hainaut,et al.  Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis , 2010, Oncogene.

[14]  G. Pelosi,et al.  Alterations of the Notch pathway in lung cancer , 2009, Proceedings of the National Academy of Sciences.

[15]  F. Cappuzzo,et al.  Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[17]  M. Schwab,et al.  Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation , 2008, Analytical and bioanalytical chemistry.

[18]  G. Mills,et al.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 , 2008, Nature Genetics.

[19]  L. Cooper,et al.  Reconstructing networks of pathways via significance analysis of their intersections , 2008, BMC Bioinformatics.

[20]  S. Wacholder,et al.  Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival , 2008, PloS one.

[21]  B. Ning,et al.  A variant of the Cockayne syndrome B gene ERCC6 confers risk of lung cancer , 2008, Human mutation.

[22]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[23]  P. Khatri,et al.  A systems biology approach for pathway level analysis. , 2007, Genome research.

[24]  M. Spitz,et al.  Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. , 2007, Cancer research.

[25]  A. Kinghorn,et al.  Silvestrol regulates G2/M checkpoint genes independent of p53 activity. , 2006, Anticancer research.

[26]  B. Hoffman,et al.  Gadd45a and Gadd45b Protect Hematopoietic Cells from UV-induced Apoptosis via Distinct Signaling Pathways, including p38 Activation and JNK Inhibition* , 2006, Journal of Biological Chemistry.

[27]  R. Weinshilboum,et al.  Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[29]  N. Brünner,et al.  The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. , 2006, Lung cancer.

[30]  D. Schwartz,et al.  CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. , 2005, Carcinogenesis.

[31]  Q. Zhan Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. , 2005, Mutation research.

[32]  Lincoln Stein,et al.  Reactome: a knowledgebase of biological pathways , 2004, Nucleic Acids Res..

[33]  David A Jones,et al.  Identification of a gadd45β 3′ Enhancer That Mediates SMAD3- and SMAD4-dependent Transcriptional Induction by Transforming Growth Factor β* , 2004, Journal of Biological Chemistry.

[34]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[35]  A. Giatromanolaki,et al.  Lactate Dehydrogenase Isoenzymes 1 and 5: Differential Expression by Neoplastic and Stromal Cells in Non-Small Cell Lung Cancer and Other Epithelial Malignant Tumors , 2003, Tumor Biology.

[36]  B. Stewart,et al.  World Cancer Report , 2003 .

[37]  M. Meyerson,et al.  Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.

[38]  F. Itoh,et al.  Smad‐dependent GADD45β expression mediates delayed activation of p38 MAP kinase by TGF‐β , 2002 .

[39]  B. Hoffman,et al.  GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress , 2002, Journal of cellular physiology.

[40]  E. Gabrielson,et al.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Sidransky,et al.  Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.

[42]  Wei Zhang,et al.  Interaction of CR6 (GADD45γ) with Proliferating Cell Nuclear Antigen Impedes Negative Growth Control* , 2001, The Journal of Biological Chemistry.

[43]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[44]  J. McVey,et al.  Tissue factor pathway. , 1994, Bailliere's best practice & research. Clinical haematology.

[45]  D. Pisetsky,et al.  Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders. , 1990, Blood.

[46]  Xia Fang,et al.  Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway. , 2016, Oncology reports.

[47]  I. Kim,et al.  PTEN / pAkt / p 53 signaling pathway correlates with the radioresponse of non-small cell lung cancer , 2010 .

[48]  細川 忍 Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer , 2010 .

[49]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[50]  D. Klassert,et al.  Molecular Cancer Chemoresistance Acquisition Induces a Global Shift of Expression of Aniogenesis-associated Genes and Increased Pro-angogenic Activity in Neuroblastoma Cells , 2009 .

[51]  A. Harris,et al.  Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. , 2005, Neoplasia.

[52]  David A Jones,et al.  Identification of a gadd45beta 3' enhancer that mediates SMAD3- and SMAD4-dependent transcriptional induction by transforming growth factor beta. , 2004, The Journal of biological chemistry.

[53]  F. Itoh,et al.  Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. , 2002, The EMBO journal.

[54]  M. Kanehisa,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[55]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[56]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[57]  J. Higginson International Agency for Research on Cancer. , 1968, WHO chronicle.